Clinical Trial Update: A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Rebif (interferon beta-1a) in subjects with clinically isolated syndrome has completed. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinically Isolated Syndrome

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Clinically Isolated Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2012-04-04